Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients With HER2 Positive Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane

NCT00684983 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00684983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00684983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients With HER2 Positive Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
July 30, 2008
Completion date
October 15, 2019
Enrollment
64 (actual)
Sites
390

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive breast carcinoma, recurrent breast carcinoma, stage iiib breast cancer ajcc v7, stage iiic breast cancer ajcc v7, stage iv breast cancer ajcc v6 and v7